A clinical trial of alpha-6-deoxyoxytetracycline (doxycycline) in the treatment of urinary tract infections.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002270:Carbuncle / Q000188:drug therapy; D002648:Child; D003556:Cystitis / Q000188:drug therapy; D004361:Drug Tolerance; D004755:Enterobacteriaceae / Q000187:drug effects; D005260:Female; D006801:Humans; D007223:Infant; D007669:Kidney Calculi / Q000150:complications; D008297:Male; D009279:Naphthacenes / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011704:Pyelonephritis / Q000188:drug therapy; D012003:Rectal Fistula / Q000150:complications; D012421:Rupture; D014522:Urethral Diseases / Q000188:drug therapy; D014523:Urethral Neoplasms / Q000188:drug therapy; D001743:Urinary Bladder / Q000293:injuries; D001744:Urinary Bladder Calculi / Q000188:drug therapy; D001745:Urinary Bladder Diseases / Q000150:complications; D001748:Urinary Bladder Neck Obstruction / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy; D014548:Urinary Fistula / Q000150:complications; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D014556:Urine / Q000382:microbiology; D014718:Vesico-Ureteral Reflux / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D009279:Naphthacenes